CRISPR Therapeutics AG (CRSP) stock
CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$40.15−0.22 (-0.54%)
Close on Nov 17, 2026Market cap $3.88BP/E –Yield –
CRISPR Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
CRISPR Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$369.58M. For fiscal 2025 it was -$345.01M. The highest annual figure on record is $538.97M in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$345.01M | – |
| FY2024 | Dec 31, 2024 | -$142.77M | – |
| FY2023 | Dec 31, 2023 | -$260.38M | – |
| FY2022 | Dec 31, 2022 | -$495.74M | -192.0% |
| FY2021 | Dec 31, 2021 | $538.97M | – |
| FY2020 | Dec 31, 2020 | -$238.37M | -520.6% |
| FY2019 | Dec 31, 2019 | $56.68M | – |
| FY2018 | Dec 31, 2018 | -$96.24M | – |
| FY2017 | Dec 31, 2017 | -$70.09M | – |
| FY2016 | Dec 31, 2016 | -$52.86M | -188.9% |
| FY2015 | Dec 31, 2015 | $59.43M | – |
| FY2014 | Dec 31, 2014 | -$4.79M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$83.50M | – |
| Q1 FY2026 | Mar 31, 2026 | -$108.90M | – |
| Q4 FY2025 | Dec 31, 2025 | -$92.55M | – |
| Q3 FY2025 | Sep 30, 2025 | -$84.63M | – |
| Q2 FY2025 | Jun 30, 2025 | -$113.88M | – |
| Q1 FY2025 | Mar 31, 2025 | -$53.95M | -149.2% |
| Q4 FY2024 | Dec 31, 2024 | -$50.03M | – |
| Q3 FY2024 | Sep 30, 2024 | -$106.91M | – |
| Q2 FY2024 | Jun 30, 2024 | -$95.58M | – |
| Q1 FY2024 | Mar 31, 2024 | $109.75M | +1147.3% |
| Q4 FY2023 | Dec 31, 2023 | -$96.07M | – |
| Q3 FY2023 | Sep 30, 2023 | -$39.86M | – |
| Q2 FY2023 | Jun 30, 2023 | -$133.25M | – |
| Q1 FY2023 | Mar 31, 2023 | $8.80M | – |
| Q4 FY2022 | Dec 31, 2022 | -$113.33M | – |
| Q3 FY2022 | Sep 30, 2022 | -$105.22M | – |
| Q2 FY2022 | Jun 30, 2022 | -$141.96M | -117.6% |
| Q1 FY2022 | Mar 31, 2022 | -$135.24M | – |
| Q4 FY2021 | Dec 31, 2021 | -$86.04M | – |
| Q3 FY2021 | Sep 30, 2021 | -$81.33M | – |
| Q2 FY2021 | Jun 30, 2021 | $807.00M | – |
| Q1 FY2021 | Mar 31, 2021 | -$100.66M | – |
| Q4 FY2020 | Dec 31, 2020 | -$81.21M | -2505.6% |
| Q3 FY2020 | Sep 30, 2020 | -$75.70M | -156.7% |
| Q2 FY2020 | Jun 30, 2020 | -$29.28M | – |
| Q1 FY2020 | Mar 31, 2020 | -$52.18M | – |
| Q4 FY2019 | Dec 31, 2019 | $3.38M | – |
| Q3 FY2019 | Sep 30, 2019 | $133.42M | – |
| Q2 FY2019 | Jun 30, 2019 | -$36.38M | – |
| Q1 FY2019 | Mar 31, 2019 | -$43.74M | – |
| Q4 FY2018 | Dec 31, 2018 | -$28.37M | – |
| Q3 FY2018 | Sep 30, 2018 | -$19.96M | – |
| Q2 FY2018 | Jun 30, 2018 | -$25.22M | – |
| Q1 FY2018 | Mar 31, 2018 | -$22.69M | – |
| Q4 FY2017 | Dec 31, 2017 | -$14.84M | – |
| Q3 FY2017 | Sep 30, 2017 | -$15.87M | – |
| Q2 FY2017 | Jun 30, 2017 | -$15.97M | – |
| Q1 FY2017 | Mar 31, 2017 | -$23.41M | – |
| Q4 FY2016 | Dec 31, 2016 | -$16.97M | – |
| Q3 FY2016 | Sep 30, 2016 | -$12.28M | – |
See a number that looks wrong?